Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CAO Craig Gracey sold 2,083 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $18.00, for a total value of $37,494.00. Following the completion of the transaction, the chief accounting officer directly owned 7,108 shares of the company’s stock, valued at approximately $127,944. This trade represents a 22.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Craig Gracey also recently made the following trade(s):
- On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The shares were sold at an average price of $17.42, for a total transaction of $120,093.48.
Omada Health Stock Performance
Shares of OMDA stock opened at $18.58 on Thursday. The firm has a fifty day moving average of $16.22 and a 200-day moving average of $14.79. The stock has a market cap of $1.10 billion and a price-to-earnings ratio of -68.81. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $26.92.
Hedge Funds Weigh In On Omada Health
A number of large investors have recently bought and sold shares of the company. Perceptive Advisors LLC acquired a new stake in shares of Omada Health in the 2nd quarter valued at approximately $44,402,000. Millennium Management LLC raised its stake in Omada Health by 1,195.0% in the 4th quarter. Millennium Management LLC now owns 2,272,168 shares of the company’s stock worth $35,855,000 after purchasing an additional 2,096,705 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Omada Health by 23.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,855,721 shares of the company’s stock valued at $29,283,000 after buying an additional 346,588 shares during the period. Divisadero Street Capital Management LP bought a new stake in shares of Omada Health during the 3rd quarter valued at $30,510,000. Finally, Jefferies Financial Group Inc. bought a new stake in Omada Health during the fourth quarter worth about $16,948,000.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the company. Wells Fargo & Company increased their target price on Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Barclays boosted their target price on Omada Health from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a research report on Friday, May 8th. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a research report on Friday, May 8th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $30.00 price target on shares of Omada Health in a research report on Monday. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.91.
Check Out Our Latest Report on Omada Health
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Articles
- Five stocks we like better than Omada Health
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
